Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sham Mailankody

Showing results (141-150 of 174) with videos related to

Pageof 18
Sort By:
Blood Cancer Discovery|November 15, 2021
Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic MalignanciesDavid J Chung, Gunjan L Shah, Sean M Devlin, et al.
American Journal of Hematology|March 4, 2021
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m<sup>2</sup> ) in combination with lenalidomide and dexamethasoneNeha Korde, Donna Mastey, Elizabet Tavitian, et al.
The New England Journal of Medicine|February 5, 2025
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in <i>TP53</i>Karlo Perica, Nayan Jain, Michael Scordo, et al.
American Journal of Hematology|October 2, 2019
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myelomaEven H Rustad, Kristine Misund, Elsa Bernard, et al.
Blood Advances|February 17, 2026
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMMKylee H Maclachlan, Carlyn Rose Tan, Tala Shekarkhand, et al.
JAMA Oncology|May 15, 2025
Barriers to Chimeric Antigen Receptor T-Cell TherapyYannis K Valtis, Kuo-Kai Chin, David Nemirovsky, et al.
Blood Advances|October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myelomaRoss S Firestone, Devin McAvoy, Tala Shekarkhand, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 27, 2020
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune ProfilingSarah A Holstein, Alan Howard, David Avigan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 2026
Respiratory Syncytial Virus After CAR T-cell therapy: Risk Factors and Outcomes in a Multicenter Retrospective CohortMaria Isabel Sotelo-Alva, Ofrat Beyar-Katz, Judy Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenanceRoss S Firestone, Anish K Simhal, Devin McAvoy, et al.
Pageof 18

Showing results (141-150 of 174) with videos related to

Sort By:
Pageof 18
Blood Cancer Discovery|November 15, 2021
Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic MalignanciesDavid J Chung, Gunjan L Shah, Sean M Devlin, et al.
American Journal of Hematology|March 4, 2021
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m<sup>2</sup> ) in combination with lenalidomide and dexamethasoneNeha Korde, Donna Mastey, Elizabet Tavitian, et al.
The New England Journal of Medicine|February 5, 2025
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in <i>TP53</i>Karlo Perica, Nayan Jain, Michael Scordo, et al.
American Journal of Hematology|October 2, 2019
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myelomaEven H Rustad, Kristine Misund, Elsa Bernard, et al.
Blood Advances|February 17, 2026
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMMKylee H Maclachlan, Carlyn Rose Tan, Tala Shekarkhand, et al.
JAMA Oncology|May 15, 2025
Barriers to Chimeric Antigen Receptor T-Cell TherapyYannis K Valtis, Kuo-Kai Chin, David Nemirovsky, et al.
Blood Advances|October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myelomaRoss S Firestone, Devin McAvoy, Tala Shekarkhand, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 27, 2020
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune ProfilingSarah A Holstein, Alan Howard, David Avigan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 2026
Respiratory Syncytial Virus After CAR T-cell therapy: Risk Factors and Outcomes in a Multicenter Retrospective CohortMaria Isabel Sotelo-Alva, Ofrat Beyar-Katz, Judy Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenanceRoss S Firestone, Anish K Simhal, Devin McAvoy, et al.
Pageof 18